title: Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.
abstract: We studied the influence of the lipid/amphotericin B (AMB) ratio and the phospholipid type on the in vitro renal cell toxicity and antifungal efficacy of lipid-associated AMB (L-AMB). L-AMB was prepared at one of two different lipid/AMB ratios (1 and 40) by incubating AMB with empty small unilamellar vesicles, made from one of three different phospholipids: dipalmitoyl-, dimirystoyl-, and distearoylphosphatidylcholine (DPPC, DMPC, and DSPC, respectively). Renal cell toxicity, investigated through an assessment of the Na-dependent uptake of phosphate by proximal tubular cells, and fungicidal effect against Candida albicans were studied after 1 h of treatment at 37 degrees C. The amount of unbound AMB present in each L-AMB formulation was studied by use of circular dichroism. At a lipid/AMB ratio of 40, the three lipidic formulations were not toxic for renal cells but were less effective against C. albicans than AMB; however, DSPC-AMB, which contained 50% unbound AMB, was more effective against C. albicans than DPCC-AMB or DMPC-AMB, containing 0 and 13% unbound AMB, respectively. At a lipid/AMB ratio of 1, the antifungal effects of L-AMB and AMB were similar, whatever the phospholipid used, but only DMPC-AMB remained highly protective against AMB renal cell toxicity, despite the presence of the same amount of unbound AMB (50%) in DMPC-AMB and DPPC-AMB. We conclude that the in vitro activities and renal cell toxicities of different L-AMB formulations are influenced by the phospholipid type and the lipid/AMB ratio. The optimal ratio depends on the phospholipid itself. At a lipid/AMB ratio of 40, the antifungal activity depends mainly on the amount of unbound AMB in the formulation. At a lipid/AMB ratio of 1, the renal cell toxicity also depends on the fluidity of the phospholipid.
authors.affiliation: Laboratoire d'Etude des Traitements Antiinfectieux, Faculté Xavier Bichat, Université Paris 7, France.
authors.forename: V
authors.initials: V
authors.lastname: Joly
authors.forename: J
authors.initials: J
authors.lastname: Bolard
authors.forename: L
authors.initials: L
authors.lastname: Saint-Julien
authors.forename: C
authors.initials: C
authors.lastname: Carbon
authors.forename: P
authors.initials: P
authors.lastname: Yeni
mesh_terms: D015060:1,2-Dipalmitoylphosphatidylcholine / Q000494:pharmacology / Q000633:toxicity; D000666:Amphotericin B / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects; D002942:Circular Dichroism; D004134:Dimyristoylphosphatidylcholine / Q000494:pharmacology / Q000633:toxicity; D004337:Drug Carriers; D007668:Kidney / Q000166:cytology* / Q000187:drug effects; D007684:Kidney Tubules / Q000166:cytology; D008297:Male; D008567:Membranes, Artificial; D010713:Phosphatidylcholines / Q000494:pharmacology / Q000633:toxicity; D010743:Phospholipids / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits
chemical_list: D000935:Antifungal Agents; D004337:Drug Carriers; D008567:Membranes, Artificial; D010713:Phosphatidylcholines; D010743:Phospholipids; D015060:1,2-Dipalmitoylphosphatidylcholine; D000666:Amphotericin B; C010942:1,2-distearoyllecithin; D004134:Dimyristoylphosphatidylcholine